Literature DB >> 9515778

Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock.

M G Vervloet1, L G Thijs, C E Hack.   

Abstract

In patients with sepsis and septic shock, both coagulation and fibrinolysis are activated frequently leading to the syndrome of diffuse intravascular coagulation (DIC). The different mechanisms leading to abnormalities in coagulation and fibrinolysis are discussed in detail. The coagulation and fibrinolytic system appear to be influenced by the septic process largely independently, leading to a procoagulant imbalance between these systems. Coagulation is initiated by mediator-induced expression of tissue factor and is associated with consumption of the natural coagulation inhibitors antithrombin III, protein C, and protein S. As a result, high plasma levels of thrombin-antithrombin complex (TAT) can be found. The effects on fibrinolysis are dominated by (highly) increased levels of plasminogen activator inhibitor type 1 (PAI-1), leading to inadequate fibrinolysis. Although levels of plasminogen activator antigen are increased, its activity is almost completely inhibited by PAI-1. The resulting effects predispose to a procoagulant state, with widespread fibrin deposition, which may be an important mechanism contributing to multiple organ failure. A thorough understanding of the pathophysiological mechanisms underlying the DIC-syndrome is a prerequisite for a rational approach and future therapy for this severe complication of sepsis.

Entities:  

Mesh:

Year:  1998        PMID: 9515778     DOI: 10.1055/s-2007-995821

Source DB:  PubMed          Journal:  Semin Thromb Hemost        ISSN: 0094-6176            Impact factor:   4.180


  30 in total

Review 1.  The host response to sepsis and developmental impact.

Authors:  James Wynn; Timothy T Cornell; Hector R Wong; Thomas P Shanley; Derek S Wheeler
Journal:  Pediatrics       Date:  2010-04-26       Impact factor: 7.124

2.  Plasminogen activator inhibitor-1 inhibits factor VIIa bound to tissue factor.

Authors:  P Sen; A A Komissarov; G Florova; S Idell; U R Pendurthi; L Vijaya Mohan Rao
Journal:  J Thromb Haemost       Date:  2011-03       Impact factor: 5.824

3.  Beneficial effect of low-molecular-weight heparin against lipopolysaccharide-induced disseminated intravascular coagulation in rats is abolished by coadministration of tranexamic acid.

Authors:  Hidesaku Asakura; Yoko Sano; Tomotaka Yoshida; Mika Omote; Yasuo Ontachi; Tomoe Mizutani; Masahide Yamazaki; Eriko Morishita; Akiyoshi Takami; Ken-ichi Miyamoto; Shinji Nakao
Journal:  Intensive Care Med       Date:  2004-06-15       Impact factor: 17.440

4.  Alterations in homeostasis after open surgery. A prospective randomized study.

Authors:  T Dedej; E Lamaj; N Marku; V Ostreni; S Bilali
Journal:  G Chir       Date:  2013 Jul-Aug

Review 5.  [Pathophysiology of acute lung injury in severe burn and smoke inhalation injury].

Authors:  M O Maybauer; S Rehberg; D L Traber; D N Herndon; D M Maybauer
Journal:  Anaesthesist       Date:  2009-08       Impact factor: 1.041

6.  Fibrinolytic and coagulation pathways after laparoscopic and open surgery: a prospective randomized trial.

Authors:  Nikos Tsiminikakis; Elie Chouillard; Christos Tsigris; Theodoros Diamantis; Christine Bongiorni; Constantinos Ekonomou; C Antoniou; Ioannis Bramis
Journal:  Surg Endosc       Date:  2009-05-15       Impact factor: 4.584

7.  Guidance on patient identification and administration of recombinant human activated protein C for the treatment of severe sepsis.

Authors:  Gary Garber; Rt Noel Gibney; Bruce Light; Claudio Martin; Kenneth Cunningham; Jean-Gilles Guimond; Sheldon Magder; James Russell
Journal:  Can J Infect Dis       Date:  2002-11

8.  Administration of C1 inhibitor reduces neutrophil activation in patients with sepsis.

Authors:  Sacha Zeerleder; Christoph Caliezi; Gerard van Mierlo; Anke Eerenberg-Belmer; Irmela Sulzer; C Erik Hack; Walter A Wuillemin
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

Review 9.  Drotrecogin alfa (activated): a novel therapeutic strategy for severe sepsis.

Authors:  S M Pastores
Journal:  Postgrad Med J       Date:  2003-01       Impact factor: 2.401

10.  Activated protein C improves survival in severe sepsis patients with elevated troponin.

Authors:  Jijo John; Ahmed Awab; Derek Norman; Tarek Dernaika; Gary T Kinasewitz
Journal:  Intensive Care Med       Date:  2007-08-08       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.